Detalhe da pesquisa
1.
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat
; 187(2): 467-476, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33748921
2.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171426
3.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581356
4.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
N Engl J Med
; 372(8): 724-34, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25693012
5.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
N Engl J Med
; 366(2): 109-19, 2012 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149875
6.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 14(6): 461-71, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23602601
7.
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Oncologist
; 18(3): 257-64, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23475636
8.
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Cancer Chemother Pharmacol
; 79(2): 353-361, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28074265
9.
Rituximab: ongoing and future clinical development.
Semin Oncol
; 29(1 Suppl 2): 105-12, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11842397
10.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol
; 29(1 Suppl 2): 36-40, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11842387
11.
Rituximab: Ongoing and future clinical development.
Semin Oncol
; 29(1S2): 105-112, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28140083
12.
Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.
Biol Blood Marrow Transplant
; 9(6): 405-13, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12813449
13.
Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
Biol Blood Marrow Transplant
; 8(10): 550-6, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12434950
14.
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol
; 29(1S2): 36-40, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28140090
15.
No clinical evidence for CD4+ cell depletion caused by rituximab.
Blood
; 102(1): 408; author reply 408-9, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12814917